AtriCure Announces the Launch of the cryoXT(TM) Device for Post-Operative Pain Management Following Amputation
MWN-AI** Summary
AtriCure, Inc. has announced the launch of its cryoXT™ device, an innovative tool designed for post-operative pain management following amputation procedures. This device aims to address a significant clinical need, as over 185,000 amputations are performed annually in the U.S., with a substantial percentage of patients suffering from residual limb and phantom limb pain. The cryoXT leverages AtriCure’s established cryoICE® platform, which is known for its unique freezing technology that blocks pain signals by ablating peripheral nerves.
Recently cleared by the FDA under 510(k) regulations, the cryoXT device seeks to enhance pain relief post-amputation through its advanced multi-surface freezing capabilities, enabling precise targeting of large diameter peripheral nerves. This new device builds on the previous success of AtriCure’s cryoSPHERE products, which have been utilized in over 100,000 procedures since their release in November 2018.
Michael Carrel, President and CEO of AtriCure, emphasized the company’s commitment to delivering impactful solutions within the surgical segment. He noted that the cryoXT device fills a crucial gap in post-amputation care, helping patients effectively manage pain and improve their overall quality of life. Orthopedic surgeon Dr. Bryan Houseman also highlighted the device's potential to significantly enhance recovery outcomes for patients by effectively managing pain during surgery.
The introduction of the cryoXT device not only expands AtriCure’s market opportunities in post-operative pain management but also enhances its portfolio of innovations aimed at improving patient care. The company continues to navigate the complexities of regulatory approvals and market acceptance as it seeks to grow its footprint in the field of surgical healthcare.
MWN-AI** Analysis
AtriCure, Inc. (NASDAQ: ATRC) recently announced the launch of its cryoXT™ device, aimed at addressing post-operative pain management for amputation patients. This innovation not only expands AtriCure’s product portfolio but also positions the company to meet a significant market need, with over 185,000 amputations occurring annually in the U.S. alone. Approximately 60% of these patients suffer from residual limb pain, highlighting a critical gap in effective pain management solutions.
The cryoXT device operates as part of the cryoICE® platform, which has already demonstrated its safety and efficacy through prior usage in over 100,000 procedures. Given the potentially high acceptance rate among healthcare providers and its FDA-approved status, the cryoXT could rapidly gain traction in surgical contexts, offering robust growth prospects for AtriCure.
From an investment standpoint, this development appears to solidify AtriCure’s competitive advantage in the healthcare sector, particularly in a niche with limited competition and high patient demand. With effective pain management solutions being a top priority for surgical teams, the cryoXT device stands poised to capture significant market share, translating to increased revenues for the company.
However, potential investors should remain cognizant of risks. Market acceptance can be unpredictable, influenced by reimbursement policies and clinical responses. Regulatory challenges also pose a risk, as AtriCure must navigate ongoing FDA scrutiny. Furthermore, macroeconomic factors could affect hospital budgets for new technology adoption.
In summary, AtriCure's launch of the cryoXT device represents a strategic move to tap into a pressing market need in post-operative care. For investors, keeping an eye on clinical adoption rates and market penetration will be crucial as the company seeks to leverage this innovation for future growth.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
New device expands AtriCure’s market opportunity in post-operative pain management while addressing a significant unmet clinical need
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced the launch of the cryoXT ™ device, an innovative cryoablation technology used to help manage post-operative pain following amputation procedures.
Each year, over 185,000 amputations occur in the U.S., with approximately 60% 1 of patients experiencing residual limb pain and up to 85% 2 reporting phantom limb pain. AtriCure’s cryoICE ® platform uses a unique freezing method to block nerve pain signals. With the introduction of the cryoXT device, physicians now have access to a next-generation tool that brings this long-lasting approach to post-amputation pain management.
Recently cleared under an FDA 510(k), the cryoXT device is designed to temporarily block pain following amputation by ablating peripheral nerves. As part of the cryoICE ® platform, the cryoXT device builds on the proven safety and efficacy of AtriCure’s cryoSPHERE devices, which have been used in over 100,000 procedures since FDA clearance in November 2018. The device features a newly designed tip with multi-surface freezing technology to precisely target large diameter exposed peripheral nerves.
“The launch of the cryoXT device reflects our commitment to bringing meaningful, differentiated solutions to patients and providers in a significant and underserved segment of the surgical market,” said Michael Carrel, President and CEO of AtriCure. “We’re addressing a clear gap in post-amputation care by helping more patients successfully manage pain. It’s a powerful combination of doing good and expanding AtriCure’s growth pathways.”
“As an orthopedic surgeon, managing long-term pain after limb loss is a critical part of patient care,” said Dr. Bryan Houseman, DO, Orthopedic Surgeon at The Elliot Hospital in Manchester, NH. “The cryoXT device allows us to address pain at the time of surgery effectively, improving both recovery and quality of life, and represents a significant advancement in reducing post-surgical pain for our patients.”
- https://journals.lww.com/pain/abstract/2021/07000/prevalence_of_residual_limb_pain_and_symptomatic.3.aspx#:~:text=The%20prevalence%20of%20RLP%20and%20symptomatic%20neuroma%20in%20patients%20who,providing%20timely%20and%20adequate%20management
- https://www.ncbi.nlm.nih.gov/books/NBK448188/
About AtriCure
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Electrophysiologists, cardiothoracic and thoracic surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications, and post-operative pain management. AtriCure’s Isolator ® Synergy ™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent and long-standing persistent Afib. AtriCure’s AtriClip ® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF ™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE ® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on X @AtriCure .
Forward-Looking Statements
Certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Actual results may differ materially from those projected by any forward-looking statements. These risks and uncertainties include, but are not limited to, the following: our estimate of the market for our products; the rate and degree of market acceptance of our products; negative clinical data, including data that does not demonstrate sufficient safety and efficacy with respect to our products; the timing of and ability to obtain and maintain regulatory clearances and approvals for our products; our ability to comply with extensive FDA regulations; the timing of and ability to obtain third party payor reimbursement of procedures utilizing our products; the impact of tariffs or other restrictive trade measures; and litigation, administrative or other proceedings. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 14, 2025, and our quarterly reports on Form 10-Q. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250909575208/en/
Angie Wirick
Investor Relations
Chief Financial Officer
(513) 755-5334
awirick@atricure.com
Valerie Storch-Willhaus
Media Relations
Vice President, Corporate Marketing & Communications
(612) 605-3311
vstorch-willhaus@atricure.com
FAQ**
How does the cryoXT device from AtriCure Inc. ATRC specifically enhance post-operative pain management compared to existing methods currently in use for amputation patients?
What is AtriCure Inc. ATRC's strategy for ensuring the widespread adoption of the cryoXT device among orthopedic surgeons and healthcare providers?
Given the significant unmet clinical need in post-amputation pain management, what market share does AtriCure Inc. ATRC anticipate capturing with the launch of the cryoXT device?
How does AtriCure Inc. ATRC plan to address potential regulatory challenges and reimbursement issues related to the cryoXT device following its FDA clearance?
**MWN-AI FAQ is based on asking OpenAI questions about AtriCure Inc. (NASDAQ: ATRC).
NASDAQ: ATRC
ATRC Trading
-1.98% G/L:
$29.21 Last:
639,601 Volume:
$29.66 Open:
